Aneta Urszula Szulc

Mrs. Aneta Urszula Szulc

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Foods
Verified
Journal Article
Open access
PDF file
ASAneta Urszula Szulc
Aneta Urszula Szulc
KWKarolina Joanna Wiśniewska
Karolina Joanna Wiśniewska
MŻMagdalena Żabińska
Magdalena Żabińska
Lidia GaffkeLidia Gaffke
Lidia Gaffke
MSMaria Szota
Maria Szota
Karolina PierzynowskaKarolina Pierzynowska
Karolina Pierzynowska
Over the past decades, there has been a significant increase in the burden of neurological diseases, including neurodegenerative disorders, on a global scale. This is linked to a widespread demographic trend in which developed societies are aging, leading to an increased proportion of elderly individuals and, concurrently, an increase in the number of those afflicted, posing one of the main public health challenges for the coming decades. The complex pathomechanisms of neurodegenerative diseases and resulting varied symptoms, which differ depending on the disease, environment, and lifestyle of the patients, make searching for therapies for this group of disorders a formidable challenge. Currently, most neurodegenerative diseases are considered incurable. An important aspect in the fight against and prevention of neurodegenerative diseases may be broadly understood lifestyle choices, and more specifically, what we will focus on in this review, a diet. One proposal that may help in the fight against the spread of neurodegenerative diseases is a diet rich in flavonoids. Flavonoids are compounds widely found in products considered healthy, such as fruits, vegetables, and herbs. Many studies indicated not only the neuroprotective effects of these compounds but also their ability to reverse changes occurring during the progression of diseases such as Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis. Here, we present the main groups of flavonoids, discussing their characteristics and mechanisms of action. The most widely described mechanisms point to neuroprotective functions due to strong antioxidant and anti-inflammatory effects, accompanied with their ability to penetrate the blood-brain barrier, as well as the ability to inhibit the formation of protein aggregates. The latter feature, together with promoting removal of the aggregates is especially important in neurodegenerative diseases. We discuss a therapeutic potential of selected flavonoids in the fight against neurodegenerative diseases, based on in vitro studies, and their impact when included in the diet of animals (laboratory research) and humans (population studies). Thus, this review summarizes flavonoids’ actions and impacts on neurodegenerative diseases. Therapeutic use of these compounds in the future is potentially possible but depends on overcoming key challenges such as low bioavailability, determining the therapeutic dose, and defining what a flavonoid-rich diet is and determining its potential negative effects. This review also suggests further research directions to address these challenges.

9 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
KWKarolina Joanna Wiśniewska
Karolina Joanna Wiśniewska
JWJakub Wolski
Jakub Wolski
MŻMagdalena Żabińska
Magdalena Żabińska
ASAneta Urszula Szulc
Aneta Urszula Szulc
Lidia GaffkeLidia Gaffke
Lidia Gaffke
Grzegorz WęgrzynGrzegorz Węgrzyn
Grzegorz Węgrzyn
Mucopolysaccharidoses (MPS) comprise a group of 12 metabolic disorders where defects in specific enzyme activities lead to the accumulation of glycosaminoglycans (GAGs) within lysosomes. This classification expands to 13 when considering MPS IIIE. This type of MPS, associated with pathogenic variants in the ARSG gene, has thus far been described only in the context of animal models. However, pathogenic variants in this gene also occur in humans, but are linked to a different disorder, Usher syndrome (USH) type IV, which is sparking increasing debate. This paper gathers, discusses, and summarizes arguments both for and against classifying dysfunctions of arylsulfatase G (due to pathogenic variants in the ARSG gene) in humans as another subtype of MPS, called MPS IIIE. Specific difficulties in diagnostics and the classification of some inherited metabolic diseases are also highlighted and discussed.

24 November 2025 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
KWKarolina Joanna Wiśniewska
Karolina Joanna Wiśniewska
MSMaria Szota
Maria Szota
MŻMagdalena Żabińska
Magdalena Żabińska
ASAneta Urszula Szulc
Aneta Urszula Szulc
Łukasz GrabowskiŁukasz Grabowski
Łukasz Grabowski
Karolina PierzynowskaKarolina Pierzynowska
Karolina Pierzynowska
Neurodegeneration with brain iron accumulation (NBIA) is a group of rare neurodegenerative disorders characterized by excessive iron deposition in the central nervous system. The disease typically manifests in early childhood with progressive dystonia, muscle rigidity, spasticity, ataxia, as well as personality changes (such as nervousness, aggression, and learning difficulties) and psychiatric symptoms (including disorientation, confusion, seizures, and dementia). The most common forms – BPAN, PKAN, MPAN, and PLAN—are associated with mutations in the WDR45, PANK2, C19orf12, and PLA2G6 genes, respectively, leading to disruptions in mitochondrial functions, autophagy, and coenzyme A metabolism. These abnormalities result in oxidative stress and neurodegeneration; however, the connection between the observed mutations and iron accumulation in the central nervous system remains unclear. There is ongoing debate as to whether iron accumulation is a primary pathological factor or a secondary consequence of cellular dysfunction. Unfortunately, despite numerous therapeutic attempts, including the use of iron chelators, treatment efficacy remains very limited. Therefore, the aim of this review was to present the latest findings on the relationship between WDR45, PANK2, C19orf12, and PLA2G6 mutations and iron metabolism disorders. The data presented may help explain the previously undescribed roles of these mutations in the excessive iron accumulation observed in the nervous system of patients with NBIA, while also highlighting the complexity of NBIA pathogenesis. A better understanding of these mechanisms may contribute to the development of new, more effective therapeutic strategies, which are greatly needed by patients.

9 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
BWBeata M. Walter
Beata M. Walter
JMJoanna Morcinek-Orłowska
Joanna Morcinek-Orłowska
ASAneta Urszula Szulc
Aneta Urszula Szulc
ALAndrew L. Lovering
Andrew L. Lovering
JHJames R.J. Haycocks
James R.J. Haycocks
MGMonika Glinkowska
Monika Glinkowska
In bacteria, post-translational acetylation of lysine residues affects the activities of numerous proteins, thus constituting an important regulatory mechanism that influences bacterial growth and adaptation to various environments. Conversely, the modification level of some lysine residues is controlled by deacetylases that remove the acetyl group. Most bacterial deacetylases are homologous to eukaryotic sirtuins, which utilize NAD+ as a cofactor. The Escherichia coli genome encodes a single sirtuin – CobB. However, both the regulation of CobB activity and the role that reversible acetylation plays in the control of protein functions and cellular pathways are not fully understood. In this study, we demonstrate that CobB forms a stable complex with PRPP synthase Prs. PRPP synthase is responsible for providing precursor metabolite for the synthesis of certain amino acids as well as nucleotides, including the cofactor NAD+. This association stimulates the deacetylation rate by CobB and protects it from inhibition by its reaction byproduct nicotinamide. We present evidence indicating that acetylation of Prs is physiologically significant and impacts E. coli metabolism and global protein acetylation level, although it does not affect CobB binding in vitro . In turn, Prs can be deacetylated by CobB, while formation of CobB-Prs complex formation safeguards PRPP synthase activity under non-optimal conditions. We propose that formation of the complex regulates deacetylation of other protein substrates by CobB.

16 December 2024 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
KWKarolina Joanna Wiśniewska
Karolina Joanna Wiśniewska
MŻMagdalena Żabińska
Magdalena Żabińska
Lidia GaffkeLidia Gaffke
Lidia Gaffke
ASAneta Urszula Szulc
Aneta Urszula Szulc
BWBeata M. Walter
Beata M. Walter
Karolina PierzynowskaKarolina Pierzynowska
Karolina Pierzynowska
Background: Mucopolysaccharidosis (MPS) is a class of hereditary metabolic diseases that demonstrate itself by accumulating incompletely degraded glycosaminoglycans (GAGs). MPS are classified according to the kind(s) of stored GAG(s) and specific genetic/enzymatic defects. Despite the accumulation of the same type of GAG, two MPS diseases, Sanfilippo (MPS III) and Morquio (MPS IV), are further distinguished into subclasses based on different enzymes that are deficient. Although genetic defects in MPS are known, molecular mechanisms of particular MPS types are still incomplete. This work aimed to investigate gene expression patterns in MPS III and MPS IV subtypes to identify dysregulated genes that could indicate unidentified molecular mechanisms of the diseases. Methods: Transcriptomic analyses were conducted to assess gene expression patterns in MPS and control cells. Western blotting and immunohistochemistry determined selected protein levels (products of the most significantly dysregulated genes). Effects of decreased levels of gene expression were investigated using small interferring RNA (siRNA)-mediated gene silencing. Results: Transcriptomic analyses indicated 45 commonly dysregulated genes among all MPS III subtypes and as many as 150 commonly dysregulated genes among both MPS IV subtypes. A few genes revealed particularly high levels of dysregulation, including PFN1, MFAP5, and MMP12. Intriguingly, elevated levels of profilin-1 (product of the PFN1 gene) could be reduced by decreasing GAG levels in genistein-treated MPS III and MPS IV cells, while silencing of PFN1 caused a significant decrease in GAG accumulation in these cells, indicating an interdependent correlation between profilin-1 and GAG levels. Conclusions: A plethora of commonly dysregulated genes were identified in MPS subtypes III and IV. Some of these genes, like PFN1, MFAP5, and MMP12, revealed highly pronounced changes in expression relative to control cells. An interdependent correlation between GAG levels and the expression of the PFN1 gene was identified. Thus, PFN1 could be suggested as a potential new therapeutic target for MPS III and IV.

Verified
Journal Article
Open access
PDF file
KWKarolina Joanna Wiśniewska
Karolina Joanna Wiśniewska
MŻMagdalena Żabińska
Magdalena Żabińska
ASAneta Urszula Szulc
Aneta Urszula Szulc
Lidia GaffkeLidia Gaffke
Lidia Gaffke
Grzegorz WęgrzynGrzegorz Węgrzyn
Grzegorz Węgrzyn
Karolina PierzynowskaKarolina Pierzynowska
Karolina Pierzynowska
Mucopolysaccharidosis (MPS) comprises a group of inherited metabolic diseases. Each MPS type is caused by a deficiency in the activity of one kind of enzymes involved in glycosaminoglycan (GAG) degradation, resulting from the presence of pathogenic variant(s) of the corresponding gene. All types/subtypes of MPS, which are classified on the basis of all kinds of defective enzymes and accumulated GAG(s), are severe diseases. However, neuronopathy only occurs in some MPS types/subtypes (specifically severe forms of MPS I and MPS II, all subtypes of MPS III, and MPS VII), while in others, the symptoms related to central nervous system dysfunctions are either mild or absent. The early diagnosis of neuronopathy is important for the proper treatment and/or management of the disease; however, there are no specific markers that could be easily used for this in a clinical practice. Therefore, in this work, a comparative analysis of shared and specific gene expression alterations in neuronopathic and non-neuronopathic MPS types was performed using cultures of cells derived from patients. Using transcriptomic analyses (based on the RNA-seq method, confirmed by measuring the levels of a selected gene product), we identified genes (including PFN1, ADAMTSL1, and ABHD5) with dysregulated expression that are common for all, or almost all, types of MPS, suggesting their roles in MPS pathogenesis. Moreover, a distinct set of genes (including ARL6IP6 and PDIA3) exhibited expression changes only in neuronopathic MPS types/subtypes, but not in non-neuronopathic ones, suggesting their possible applications as biomarkers for neurodegeneration in MPS. These findings provide new insights into both the molecular mechanisms of MPS pathogenesis and the development of differentiation method(s) between neuronopathic and non-neuronopathic courses of the disease.